Show simple item record

dc.contributor.authorVan der Kolk, WLen_US
dc.contributor.authorVan der Zee, AGJen_US
dc.contributor.authorSlomovitz, BMen_US
dc.contributor.authorBaldwin, PJWen_US
dc.contributor.authorVan Doorn, HCen_US
dc.contributor.authorDe Hullu, JAen_US
dc.contributor.authorVan der Velden, Jen_US
dc.contributor.authorGaarenstroom, KNen_US
dc.contributor.authorSlangen, BFMen_US
dc.contributor.authorKjolhede, Pen_US
dc.contributor.authorBrännström, Men_US
dc.contributor.authorVergote, Ien_US
dc.contributor.authorHolland, CMen_US
dc.contributor.authorColeman, Ren_US
dc.contributor.authorVan Dorst, EBLen_US
dc.contributor.authorVan Driel, WJen_US
dc.contributor.authorNunns, Den_US
dc.contributor.authorWidschwendter, Men_US
dc.contributor.authorNugent, Den_US
dc.contributor.authorDiSilvestro, PAen_US
dc.contributor.authorMannel, RSen_US
dc.contributor.authorTjiong, MYen_US
dc.contributor.authorBoll, Den_US
dc.contributor.authorCibula, Den_US
dc.contributor.authorCovens, Aen_US
dc.contributor.authorProvencher, Den_US
dc.contributor.authorRunnebaum, IBen_US
dc.contributor.authorMonk, BJen_US
dc.contributor.authorZanagnolo, Ven_US
dc.contributor.authorTamussino, Ken_US
dc.contributor.authorOonk, MHMen_US
dc.contributor.authorall GROINSS-V I and II participantsen_US
dc.date.accessioned2022-11-16T11:43:58Z
dc.date.available2022-07-18en_US
dc.date.issued2022-10en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/82483
dc.description.abstractOBJECTIVE: Optimal management of the contralateral groin in patients with early-stage vulvar squamous cell carcinoma (VSCC) and a metastatic unilateral inguinal sentinel lymph node (SN) is unclear. We analyzed patients who participated in GROINSS-V I or II to determine whether treatment of the contralateral groin can safely be omitted in patients with a unilateral metastatic SN. METHODS: We selected the patients with a unilateral metastatic SN from the GROINSS-V I and II databases. We determined the incidence of contralateral additional non-SN metastases in patients with unilateral SN-metastasis who underwent bilateral inguinofemoral lymphadenectomy (IFL). In those who underwent only ipsilateral groin treatment or no further treatment, we determined the incidence of contralateral groin recurrences during follow-up. RESULTS: Of 1912 patients with early-stage VSCC, 366 had a unilateral metastatic SN. Subsequently, 244 had an IFL or no treatment of the contralateral groin. In seven patients (7/244; 2.9% [95% CI: 1.4%-5.8%]) disease was diagnosed in the contralateral groin: five had contralateral non-SN metastasis at IFL and two developed an isolated contralateral groin recurrence after no further treatment. Five of them had a primary tumor ≥30 mm. Bilateral radiotherapy was administered in 122 patients, of whom one (1/122; 0.8% [95% CI: 0.1%-4.5%]) had a contralateral groin recurrence. CONCLUSION: The risk of contralateral lymph node metastases in patients with early-stage VSCC and a unilateral metastatic SN is low. It appears safe to limit groin treatment to unilateral IFL or inguinofemoral radiotherapy in these cases.en_US
dc.format.extent3 - 10en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofGynecol Oncolen_US
dc.rightsThis is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
dc.subjectInguinofemoral lymphadenectomyen_US
dc.subjectLymph node metastasesen_US
dc.subjectRadiotherapyen_US
dc.subjectSentinel lymph nodeen_US
dc.subjectVulvar canceren_US
dc.subjectCarcinoma, Squamous Cellen_US
dc.subjectFemaleen_US
dc.subjectGroinen_US
dc.subjectHumansen_US
dc.subjectLymph Node Excisionen_US
dc.subjectLymph Nodesen_US
dc.subjectLymphadenopathyen_US
dc.subjectLymphatic Metastasisen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectSentinel Lymph Nodeen_US
dc.subjectSentinel Lymph Node Biopsyen_US
dc.subjectVulvar Neoplasmsen_US
dc.titleUnilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe.en_US
dc.typeArticle
dc.rights.holder© 2022 The Authors. Published by Elsevier Inc.
dc.identifier.doi10.1016/j.ygyno.2022.07.017en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36085090en_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume167en_US
dcterms.dateAccepted2022-07-18en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record